The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies
Kurt Stocker, Matthias Hartmann, Laura Ley, Friederike Holze, Anna M Becker, Matthias E. Liechti
Journal of Psychopharmacology October 31, 2023 DOI: 10.1177/02698811231199112 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Exploratory and confirmatory factor analysis Peer reviewed |
|---|---|
| Sample size | 140 |
| Population | Healthy participants |
| Interventions | Lysergic acid diethylamide Psilocybin |
| Dose | moderate to high doses |
| Topics | Mysticism Psilocybin LSD Mystical experience |
| Keywords | Psychometrics Exploratory factor analysis Confirmatory factor analysis Clinical psychology Experiential avoidance |
| Citations | 22 |
| Key points | Four new subscales—paradoxicality, connectedness, visual experience, and distressing experience—were identified in the PES beyond the MEQ30, and adding them to the MEQ30 increased explained variance with the 5D-ASC. |
Abstract
Background: Research with the Psychedelic Experience Questionnaire/Scale (PES) focuses on questions relating to mystical experience (Mystical Experience Questionnaire (MEQ)). The psychometric potential of the non-MEQ items of the PES remains largely unexplored.
Aims: We investigated whether the PES also yields subscales besides the MEQ30 subscales.
Methods: Data from 239 PES measurements (140 healthy participants) from six studies with moderate to high doses of lysergic acid diethylamide and/or psilocybin were included. New subscales (with items other than MEQ30) were created and validated as follows: (1) theoretical derivation of candidate items; (2) removal of items with rare experiences; (3) exploratory factor analysis; and (4) confirmatory factor analysis. Correlations of subscales within the PES and between the PES and the 5-Dimensional Altered States of Consciousness Scale (5D-ASC) were performed. In addition, a cluster analysis using all items (except rare experiences) was performed.
Results: The reliability of the four original factors of the MEQ30 was confirmed and four additional factors for the non-MEQ items were revealed: paradoxicality, connectedness, visual experience, and distressing experience. The first two additional factors were strongly correlated with the MEQ30 mystical subscale. Adding the new subscales to the MEQ30 subscales increased the explained variance with the 5D-ASC. The cluster analysis confirmed our main results and provided additional insights for future psychedelic psychometrics.
Conclusion: The study yields a new validated 6-factor structure for extended mystical experience (MEQ40: MEQ30 + Paradoxicality + Connectedness) and covers psychedelic experience as a whole more comprehensively than has hitherto been possible within a single questionnaire (PES48). The entire PES (PES100) can also be used for further future psychedelic-psychometric research.
Citations in the library
Cited by 24
- Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants. Neuropsychopharmacology December 1, 2024
- Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre‐Administration in a Randomized, Double‐Blind, Cross‐Over Phase I Trial Clinical Pharmacology & Therapeutics February 28, 2025
- Methylenedioxymethamphetamine is a connectogen with empathogenic, entactogenic, and still further connective properties: It is time to reconcile “the great entactogen—empathogen debate” Journal of Psychopharmacology July 28, 2024
- Classification schemes of altered states of consciousness. Neuroscience & Biobehavioral Reviews August 1, 2025
- Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants Neuropsychopharmacology December 19, 2024
and 19 more in the library
Cites 32
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology December 1, 2011
and 27 more in the library